Develops therapies for rare diseases and biodefense applications, focusing on vaccines and treatments for inflammatory diseases.
Soligenix, Inc. is an advanced biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases across the United States. The company operates through two distinct segments: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics segment, Soligenix focuses on advancing SGX301 (HyBryte), a novel photodynamic therapy that has successfully completed Phase III clinical trials for the treatment of cutaneous T-cell lymphoma. Additionally, SGX942, utilizing innate defense regulator technology, is undergoing Phase III trials for managing inflammatory conditions, specifically oral mucositis in head and neck cancer patients. The segment also includes proprietary formulations like oral beclomethasone 17,21-dipropionate variants such as SGX203 for pediatric Crohn's disease and SGX302, currently in Phase I/II trials for mild-to-moderate psoriasis treatment.
In its Public Health Solutions segment, Soligenix is focused on developing RiVax, a promising ricin toxin vaccine candidate that has successfully completed Phase Ia and Ib clinical trials. The segment also includes SGX943, a therapeutic candidate in pre-clinical stages targeting antibiotic-resistant and emerging infectious diseases, along with ThermoVax, a technology under pre-clinical development for stabilizing vaccines. Additionally, Soligenix is actively pursuing CiVax, a vaccine candidate in pre-clinical stages for COVID-19 prevention. Originally founded as DOR BioPharma, Inc. and rebdranded in 2009, Soligenix, Inc. has been at the forefront of biopharmaceutical innovation since its incorporation in 1987. Headquartered in Princeton, New Jersey, the company continues to push boundaries in rare disease treatment and public health solutions, driven by a commitment to improving patient outcomes and addressing unmet medical needs globally.